199 related articles for article (PubMed ID: 33263945)
1. Challenges in sarcoidosis and sarcoid-like reactions associated to immune checkpoint inhibitors: A narrative review apropos of a case.
Apalla Z; Kemanetzi C; Papageorgiou C; Bobos M; Manoli M; Fotiadou C; Hatzibougias D; Boukovinas I; Stergiou E; Levva S; Lallas A; Lazaridou E
Dermatol Ther; 2021 Jan; 34(1):e14618. PubMed ID: 33263945
[TBL] [Abstract][Full Text] [Related]
2. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
Chorti E; Kanaki T; Zimmer L; Hadaschik E; Ugurel S; Gratsias E; Roesch A; Bonella F; Wessendorf TE; Wälscher J; Theegarten D; Schadendorf D; Livingstone E
Eur J Cancer; 2020 May; 131():18-26. PubMed ID: 32248071
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation.
Chanson N; Ramos-Casals M; Pundole X; Suijkerbuijk K; José de Barros E Silva M; Lidar M; Benesova K; Leipe J; Acar-Denizli N; Pradère P; Michot JM; Voisin AL; Suárez-Almazor ME; Radstake TRD; Fernandes Moça Trevisani V; Schulze-Koops H; Melin A; Robert C; Mariette X; Baughman RP; Lambotte O; ; ; ; ; ;
Eur J Cancer; 2021 Nov; 158():208-216. PubMed ID: 34452793
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z
Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873
[TBL] [Abstract][Full Text] [Related]
5. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
Tan I; Malinzak M; Salama AKS
J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
[TBL] [Abstract][Full Text] [Related]
6. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients.
Tetzlaff MT; Nelson KC; Diab A; Staerkel GA; Nagarajan P; Torres-Cabala CA; Chasen BA; Wargo JA; Prieto VG; Amaria RN; Curry JL
J Immunother Cancer; 2018 Feb; 6(1):14. PubMed ID: 29433571
[TBL] [Abstract][Full Text] [Related]
7. Toxic epidermal necrolysis occurring with immune checkpoint inhibitors.
Gopee NH; Gourley AM; Oliphant TJ; Hampton PJ
Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941713
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
9. Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors.
Cao Y; Afzal MZ; Gutmann EJ; Shirai K
Melanoma Res; 2024 Feb; 34(1):70-75. PubMed ID: 37830935
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy-induced exclusively cutaneous sarcoid-like reaction.
Mazumder A; Mehrmal S; Chaudhry S
BMJ Case Rep; 2023 Jul; 16(7):. PubMed ID: 37463781
[TBL] [Abstract][Full Text] [Related]
11. Sarcoid-like reactions in patients receiving modern melanoma treatment.
Dimitriou F; Frauchiger AL; Urosevic-Maiwald M; Naegeli MC; Goldinger SM; Barysch M; Franzen D; Kamarachev J; Braun R; Dummer R; Mangana J
Melanoma Res; 2018 Jun; 28(3):230-236. PubMed ID: 29485531
[TBL] [Abstract][Full Text] [Related]
12. Sarcoid-like Reactions to Immune Checkpoint Inhibitors.
Torrecilla-Vall-Llossera C; Jucglà Serra A; Molinero Caturla J; Moreno-Vílchez C; Penín Mosquera RM; Marcoval Caus J
Actas Dermosifiliogr; 2024 Jan; 115(1):80-83. PubMed ID: 37482293
[TBL] [Abstract][Full Text] [Related]
13. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors.
Firwana B; Ravilla R; Raval M; Hutchins L; Mahmoud F
J Oncol Pharm Pract; 2017 Dec; 23(8):620-624. PubMed ID: 27590328
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma.
Danlos FX; Pagès C; Baroudjian B; Vercellino L; Battistella M; Mimoun M; Jebali M; Bagot M; Tazi A; Lebbé C
Chest; 2016 May; 149(5):e133-6. PubMed ID: 27157227
[TBL] [Abstract][Full Text] [Related]
15. Sarcoid-like reactions to immune checkpoint inhibitors: Incidence, treatment course, and impact on cancer progression and survival.
Smith H; Easterling R; Ma J; Moodabagil M; Meara A; Owen DH; Crouser E; Singha A; Ho K
Respir Med; 2024 Jun; 227():107640. PubMed ID: 38648910
[TBL] [Abstract][Full Text] [Related]
16. Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma.
Reddy SB; Possick JD; Kluger HM; Galan A; Han D
J Immunother; 2017 Oct; 40(8):307-311. PubMed ID: 28737620
[TBL] [Abstract][Full Text] [Related]
17. Volume increase of spleen in melanoma patients undergoing immune checkpoint blockade.
Susok L; Reinert D; Lukas C; Stockfleth E; Gambichler T
Immunotherapy; 2021 Aug; 13(11):885-891. PubMed ID: 34229447
[TBL] [Abstract][Full Text] [Related]
18. Hilar/mediastinal and cutaneous drug-induced sarcoidosis-like reaction associated with immune checkpoint inhibitors in metastatic colorectal cancer: a case report.
Sagawa T; Sato Y; Nagashima H; Takada K; Takahashi M; Hirakawa M; Hamaguchi K; Tamura F; Fujikawa K; Okamoto K; Kawano Y; Sogabe M; Miyamoto H; Takayama T
Front Immunol; 2023; 14():1203621. PubMed ID: 37492584
[TBL] [Abstract][Full Text] [Related]
19. Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature.
Reuss JE; Kunk PR; Stowman AM; Gru AA; Slingluff CL; Gaughan EM
J Immunother Cancer; 2016; 4():94. PubMed ID: 28031822
[TBL] [Abstract][Full Text] [Related]
20. Mediastinal FDG-positive lymph nodes simulating melanoma progression: drug-induced sarcoidosis like/lymphadenopathy related to ipilimumab.
González-Cruz C; Bodet D; Muñoz-Couselo E; García-Patos V
BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33509865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]